MedTrace Logo

GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3)

NCT07673666 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1372

Last updated 2026-06-29

No results posted yet for this study

Summary

The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-Astro23 can help detect a specific molecular type of brain tumour called IDH mutant Astrocytoma (grade 2 and 3) using routine MRI scans. The study uses previously collected and fully anonymised MRI data from 1,372 patients from 13 institutions in the Cancer Imaging Archive (TCIA).

The main questions it aims to answer are:

* How accurately can GliomaAI-Astro23 identify IDH mutant Astrocytoma (grade 2 and 3) from MRI scans?
* How well does the system perform across data from different hospitals and patient groups?

Researchers will use existing MRI scans and clinical information to train and test the AI system. No new scans, treatments, or hospital visits are required for participants, and all data used is fully anonymised and obtained from an existing research database.

Participants will not be asked to do anything, as this study only uses previously collected imaging data.

Conditions

  • Glioma
  • Glioma (Diagnosis)
  • Astrocytoma
  • Astrocytoma of Brain
  • Astrocytoma, Grade II
  • Astrocytoma, IDH-Mutant, Grade 2
  • Astrocytoma, IDH-Mutant, Grade 3

Interventions

DEVICE

GliomaAI-Astro23

Software as Medical Device (SaMD) for predicting astrocytoma (grade 2 and 3)

Sponsors & Collaborators

  • Deep Learning Institute of Radiological Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-14
Primary Completion
2021-03-09
Completion
2021-07-16
FDA Device
Yes

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07673666 on ClinicalTrials.gov